Diagnostic delay stages and pre-diagnostic treatment in patients with suspected rheumatic diseases before special care consultation: results of a multicenter-based study.

Delayed diagnosis Diagnostic delay Health service research Outcome research Time to therapy Triage

Journal

Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885

Informations de publication

Date de publication:
03 2023
Historique:
received: 15 08 2022
accepted: 27 09 2022
pubmed: 11 10 2022
medline: 3 3 2023
entrez: 10 10 2022
Statut: ppublish

Résumé

Early and effective discrimination (triage) of patients with inflammatory rheumatic diseases (IRD) and other diseases (non-IRD) is essential for successful treatment and preventing damage. The aim of this study was to investigate diagnostic delays and pre-diagnosis treatment in patients newly presenting to rheumatology outpatient clinics. A total of 600 patients newly presenting to one university hospital and two non-academic centers were included. Time from onset of symptoms to rheumatology consultation "total delay" as well as medical treatment before consultation were recorded. Median time from symptom onset to rheumatologist appointment (total delay) was 30 weeks. Median time to online search, first physician appointment request and first physician appointment was 2, 4 and 5 weeks, respectively. Total delay was significantly shorter for IRD patients compared to non-IRD patients, 26 vs 35 weeks (p = 0.007). Only 17.7% of all patients and 22.9% of IRD patients had a delay of less than 12 weeks. Total delay was significantly lower in patients seen in non-academic centers compared to the university center, 20 vs 50 weeks (p < 0.0001). 32.2% of IRD patients received medical treatment that eased their symptoms prior to the rheumatology appointment. These findings highlight the persistent diagnostic delays in rheumatology; however, they also suggest that current triage strategies effectively lead to earlier appointments for IRD patients. Improvement of triage methods and pre-diagnosis treatment could decrease overall burden of disease in IRD patients.

Identifiants

pubmed: 36214864
doi: 10.1007/s00296-022-05223-z
pii: 10.1007/s00296-022-05223-z
pmc: PMC9968271
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-502

Subventions

Organisme : Novartis
ID : 33419272

Informations de copyright

© 2022. The Author(s).

Références

Ann Rheum Dis. 2022 Aug;81(8):1065-1071
pubmed: 35470160
Rheumatology (Oxford). 2018 Sep 1;57(9):1592-1601
pubmed: 29850885
Med Klin Intensivmed Notfmed. 2016 Sep;111(6):565-6
pubmed: 27432010
Lancet. 2017 Jun 10;389(10086):2338-2348
pubmed: 28612748
Arthritis Rheum. 2010 Dec;62(12):3537-46
pubmed: 20722031
Ann Rheum Dis. 2013 Jan;72(1):13-22
pubmed: 22532640
Z Rheumatol. 2010 Dec;69(10):910-8
pubmed: 21088969
RMD Open. 2022 Sep;8(2):
pubmed: 36104118
Z Rheumatol. 2020 Oct;79(8):729-736
pubmed: 32696075
Front Public Health. 2022 Feb 22;10:844669
pubmed: 35273944
Rheumatology (Oxford). 2019 Sep 1;58(9):1634-1638
pubmed: 30903141
BMJ Open. 2019 Mar 4;9(3):e024361
pubmed: 30837252
Eur J Gen Pract. 2015;21(4):231-7
pubmed: 26679974
Ann Rheum Dis. 2015 Mar;74(3):e12
pubmed: 24534758
JMIR Mhealth Uhealth. 2020 Aug 12;8(8):e19661
pubmed: 32678796
Ann Rheum Dis. 2017 Jun;76(6):948-959
pubmed: 27979873
Z Rheumatol. 2017 Apr;76(3):195-207
pubmed: 28364218
RMD Open. 2019 Apr 3;5(1):e000870
pubmed: 31168406
RMD Open. 2021 Feb;7(1):
pubmed: 33622673
Int J Rheum Dis. 2021 Aug;24(8):1061-1070
pubmed: 34232556
Rheumatol Int. 2022 Dec;42(12):2167-2176
pubmed: 36087130
BMJ. 2015 Jul 08;351:h3727
pubmed: 26156750
Z Rheumatol. 2019 Oct;78(8):692-697
pubmed: 31468164
Arthritis Res Ther. 2021 Apr 13;23(1):112
pubmed: 33849654

Auteurs

Franziska Fuchs (F)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Harriet Morf (H)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Jacob Mohn (J)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Felix Mühlensiepen (F)

Faculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Neuruppin, Germany.

Yuriy Ignatyev (Y)

Faculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Neuruppin, Germany.

Daniela Bohr (D)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Elizabeth Araujo (E)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Christina Bergmann (C)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

David Simon (D)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Arnd Kleyer (A)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Wolfgang Vorbrüggen (W)

Verein Zur Förderung Der Rheumatologie E.V, Würselen, Germany.
RheumaDatenRhePort (rhadar), Planegg, Germany.

Andreas Ramming (A)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Jörg H W Distler (JHW)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Peter Bartz-Bazzanella (P)

RheumaDatenRhePort (rhadar), Planegg, Germany.
Klinik Für Internistische Rheumatologie, Rhein-Maas Klinikum, Würselen, Germany.

Georg Schett (G)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Martin Welcker (M)

Klinik Für Internistische Rheumatologie, Rhein-Maas Klinikum, Würselen, Germany.
MVZ Für Rheumatologie Dr. Martin Welcker GmbH, Planegg, Germany.

Axel J Hueber (AJ)

Division of Rheumatology, Paracelsus Medical University, Klinikum Nürnberg, Nuremberg, Germany.
Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany.

Johannes Knitza (J)

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany. johannes.knitza@uk-erlangen.de.
Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. johannes.knitza@uk-erlangen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH